Human medicines European public assessment report (EPAR): Busilvex, busulfan, Hematopoietic Stem Cell Transplantation, Date of authorisation: 09/07/2003, Revision: 19, Status: Withdrawn

Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Respiratory Tract Infections, Date of authorisation: 27/10/2020, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pifeltro, doravirine, HIV Infections, Date of authorisation: 22/11/2018, Revision: 9, Status: Authorised

EMA communication perception survey report 2022

Human medicines European public assessment report (EPAR): Delstrigo, doravirine,lamivudine,tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Ristfor, sitagliptin,metformin hydrochloride, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 15/07/2008, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Janumet, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 16/07/2008, Date of refusal: 18/02/2009, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Influenza, Human, Date of authorisation: 20/05/2020, Revision: 7, Status: Authorised

Declaration of interests: Patrice Verpillat